Skip to main
BFRI
BFRI logo

Biofrontera (BFRI) Stock Forecast & Price Target

Biofrontera (BFRI) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biofrontera Inc. is positioned for potential revenue acceleration with new indications for the treatment of superficial Basal Cell Carcinoma and Actinic Keratoses expected to reach the market in 2026 and 2027. The company is also likely to benefit from an increase in sales personnel and favorable reimbursement conditions, which enhance Ameluz's competitive position against cryotherapy and could drive customer conversions to photodynamic therapy. Furthermore, historical sales trends indicate that the fourth quarter will be crucial for revenue growth, especially with the new labeling that permits a higher dosage of Ameluz, increasing the potential for sales in this key period.

Bears say

Biofrontera Inc. is facing a significant challenge as its revenue of $8.6 million fell short of both the $10.6 million estimate and the consensus, indicating potential difficulties in meeting financial expectations. Furthermore, the revised stock outlook suggests a decrease in valuation, with expectations of trading at approximately 3x 2026 revenue, down from a prior target of $7 per share to $2.75 per share. Additionally, the risk of regulatory surprises looms, which could adversely affect revenue streams and lead to increased operating costs, further complicating the company's financial landscape.

Biofrontera (BFRI) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biofrontera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biofrontera (BFRI) Forecast

Analysts have given Biofrontera (BFRI) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Biofrontera (BFRI) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biofrontera (BFRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.